What are the recommended dosing regimens for Tolvaptan (generic name) for treating hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) and for autosomal dominant polycystic kidney disease (ADPKD)?

Tolvaptan Dosing Recommendations

For ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Start tolvaptan at 45 mg upon waking plus 15 mg eight hours later, then titrate weekly to a target of 90 mg AM/30 mg PM to slow kidney disease progression and reduce complications. 1

Initiation and Titration Protocol

The 2025 KDIGO guidelines provide a clear dosing algorithm 1:

• Initial dose: 45 mg in the morning + 15 mg eight hours later
• First titration (after ≥1 week): 60 mg AM + 30 mg PM
• Target dose: 90 mg AM + 30 mg PM
• Duration: Continue until approaching kidney replacement therapy

When to Reduce or Hold Tolvaptan

Consider downtitration or holding in these situations 1:

• Concurrent strong CYP3A inhibitors (itraconazole, ketoconazole, clarithromycin, protease inhibitors) or moderate inhibitors (fluconazole, erythromycin, diltiazem, verapamil, grapefruit juice)
• Intolerance or side effects (polyuria, nocturia, thirst)
• Elevated liver enzymes (see monitoring below)

Critical Monitoring Requirements

Liver function tests are mandatory 1:

• Monthly for first 18 months, then every 3 months until discontinuation
• Draw morning blood samples before tolvaptan dose
• Monitor serum sodium to assess adequate water intake

Hold tolvaptan immediately if 1:

• AST/ALT ≥3× upper limit of normal (ULN) OR >2× baseline
• AST/ALT >2× ULN with symptoms of liver injury (fatigue, nausea, vomiting, right upper quadrant pain, jaundice, pruritus)
• Repeat LFTs within 48-72 hours and assess for other causes

Permanently discontinue if 1:

• Transaminases remain ≥3× ULN without alternative explanation
• Signs/symptoms consistent with hepatic injury develop

Important Clinical Considerations

Tolvaptan reduces eGFR decline by 1.3 ml/min/1.73 m² per year and total kidney volume growth by 2.7%, while also reducing UTIs, kidney stones, hematuria, and kidney pain 1. Treatment can continue in patients >55 years or with eGFR <25 ml/min/1.73 m² if well tolerated 1.

Patients need a "sick-day plan" 1: Skip doses during volume depletion risk (limited water access, increased fluid losses, warm weather activities). Counsel patients to drink sugar-free, fat-free liquids and adopt low-sodium intake to reduce polyuria 1.

---

For SIADH/Hyponatremia

Start tolvaptan at 15 mg once daily in hospitalized patients with close sodium monitoring, titrating at ≥24-hour intervals to 30 mg, then 60 mg maximum as needed to raise serum sodium. 2

FDA-Approved Dosing for Hyponatremia

The FDA label mandates specific protocols 2:

• Setting: Must initiate and re-initiate in hospital with close serum sodium monitoring
• Starting dose: 15 mg once daily
• Titration: Increase at ≥24-hour intervals to 30 mg daily, then maximum 60 mg daily
• Goal: Raise serum sodium to >135 mEq/L
• Duration: Limit to 30 days maximum due to hepatotoxicity risk 2

Critical Safety Measures

Avoid overly rapid correction 2:

• Target <12 mEq/L increase per 24 hours to prevent osmotic demyelination syndrome
• Check sodium at 8 hours after first dose, then daily for 72 hours
• Avoid fluid restriction in first 24 hours if possible (87% of trial patients had no restriction) 2

Contraindications 2:

• Hypovolemic hyponatremia
• Inability to respond to thirst
• Anuria
• Concomitant strong CYP3A inhibitors
• ADPKD (outside FDA-approved REMS program)

Alternative Lower-Dose Strategy

Recent real-world evidence suggests 7.5 mg starting dose may reduce overcorrection risk while maintaining efficacy 3, 4, 5, 6. In a 2025 study, 7.5 mg produced mean sodium increase of 4.54 mmol/L at 4-12 hours with only 8.7% exceeding 10 mmol/L increase (versus higher rates with 15 mg) 3. Overcorrection risk increases dramatically when baseline sodium ≤127 mmol/L (OR 13.64) 3.

If using 7.5 mg approach 3, 6:

• Monitor sodium at 12 and 24 hours after first dose
• Second dose can be 7.5 mg or 15 mg depending on initial response
• Check sodium ~24 hours after second dose
• This is off-label but supported by multiple real-world studies 4, 5, 6, 7

Clinical Efficacy Data

In the SALT-1 and SALT-2 trials, tolvaptan 15-60 mg increased serum sodium by 3.7 mEq/L (baseline to day 4) and 4.6 mEq/L (baseline to day 30) versus placebo 2. Effects were seen as early as 8 hours and maintained for 30 days, with significantly less need for fluid restriction (14% vs 25%, p=0.0017) 2.

Common Pitfalls to Avoid

• Do not use for urgent correction: Patients requiring immediate sodium increase for serious neurological symptoms should receive hypertonic saline, not tolvaptan 2
• Avoid hypertonic saline combination: Do not use tolvaptan with hypertonic saline 2
• Monitor potassium: Check levels in patients with K+ >5 mEq/L or on drugs increasing potassium (ACE inhibitors, ARBs, potassium-sparing diuretics) 2
• Ensure urinary outflow: Urinary output must be secured before initiating 2

Sodium levels decline back to baseline within 7 days of discontinuation, so tolvaptan does not provide sustained benefit after stopping 2.